AI Engines For more Details: Perplexity Kagi Labs You
Ovarian Cancer: Topotecan is approved for the treatment of advanced ovarian cancer in patients who have relapsed after prior chemotherapy. It may be used alone or in combination with other chemotherapy agents to slow down the growth of ovarian cancer cells and improve survival outcomes.
Small Cell Lung Cancer: Topotecan is indicated for the treatment of small cell lung cancer (SCLC) in patients who have relapsed after initial chemotherapy. It works by interfering with the growth and replication of cancer cells in the lungs, helping to shrink tumors and delay disease progression.
Cervical Cancer: Topotecan is used in the treatment of advanced cervical cancer that has recurred or progressed despite previous therapy. It may be administered as a single agent or in combination with other chemotherapeutic agents to target cancer cells in the cervix and surrounding tissues.
Uterine Cancer: In some cases, topotecan may be considered as a treatment option for uterine cancer, particularly in patients with advanced or recurrent disease. It can help inhibit the growth of cancerous cells in the uterus and may be used alone or in combination with other medications.
Brain Tumors: Topotecan has shown activity against certain types of brain tumors, particularly those arising from neuroectodermal tissues. It may be used off-label or as part of clinical trials for the treatment of brain tumors such as glioblastoma multiforme or medulloblastoma.
Metastatic Disease: Topotecan may be used in the treatment of metastatic cancer that has spread from its primary site to other parts of the body. It can help control the spread of cancer cells and alleviate symptoms associated with metastatic disease, although it may not cure the cancer.
Hematological Malignancies: In addition to solid tumors, topotecan has shown efficacy in the treatment of certain hematological malignancies, such as leukemia and lymphoma. It may be used as salvage therapy in patients with relapsed or refractory disease.
Side Effects: Topotecan treatment is associated with various side effects, including bone marrow suppression (neutropenia, thrombocytopenia, anemia), nausea, vomiting, diarrhea, fatigue, hair loss (alopecia), mucositis, and increased susceptibility to infections. Close monitoring and supportive care are essential to manage these side effects effectively.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 1.6 | 0.3 | 4.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 0.7 | 0.4 | 0.75 |
| Allergies | 1.1 | 0.8 | 0.38 |
| Allergy to milk products | 0.5 | 0.4 | 0.25 |
| Alopecia (Hair Loss) | 0.2 | 0.2 | |
| Alzheimer's disease | 1.4 | 1.7 | -0.21 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.4 | 0.5 | -0.25 |
| Ankylosing spondylitis | 0.6 | 0.3 | 1 |
| Anorexia Nervosa | 1 | 1.1 | -0.1 |
| Antiphospholipid syndrome (APS) | 0.9 | 0.9 | |
| Asthma | 1.2 | 1.2 | 0 |
| Atherosclerosis | 0.3 | 1.3 | -3.33 |
| Atrial fibrillation | 1 | 0.4 | 1.5 |
| Autism | 3.1 | 2.1 | 0.48 |
| Autoimmune Disease | 0.3 | 0.5 | -0.67 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 1 | 1.1 | -0.1 |
| Brain Trauma | 0.3 | 0.8 | -1.67 |
| Breast Cancer | 0.3 | -0.3 | |
| Carcinoma | 1.3 | 0.7 | 0.86 |
| Celiac Disease | 0.9 | 0.9 | 0 |
| Cerebral Palsy | 0.4 | 0.8 | -1 |
| Chronic Fatigue Syndrome | 1.9 | 0.8 | 1.37 |
| Chronic Kidney Disease | 0.7 | 0.7 | 0 |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.8 | -1 |
| Chronic Urticaria (Hives) | 0.3 | 0.2 | 0.5 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1.1 | -0.57 |
| Cognitive Function | 1.6 | 0.8 | 1 |
| Colorectal Cancer | 2.6 | 0.5 | 4.2 |
| Constipation | 0.3 | 0.5 | -0.67 |
| Coronary artery disease | 0.6 | 0.5 | 0.2 |
| COVID-19 | 1.8 | 2.6 | -0.44 |
| Crohn's Disease | 2.2 | 1.6 | 0.38 |
| cystic fibrosis | 0.5 | -0.5 | |
| deep vein thrombosis | 1 | 1.1 | -0.1 |
| Denture Wearers Oral Shifts | 0.4 | 0.4 | |
| Depression | 3.7 | 3.1 | 0.19 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.3 | 0.4 | -0.33 |
| Endometriosis | 0.7 | 0.8 | -0.14 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 0.4 | 0.8 | -1 |
| Fibromyalgia | 1.3 | 1.3 | |
| Functional constipation / chronic idiopathic constipation | 1.6 | 1.3 | 0.23 |
| gallstone disease (gsd) | 0.7 | 0.7 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | -0.3 | |
| Generalized anxiety disorder | 0.7 | 1 | -0.43 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.7 | 0.4 | 0.75 |
| Graves' disease | 0.7 | 1.1 | -0.57 |
| Gulf War Syndrome | 0.3 | 0.4 | -0.33 |
| Halitosis | 0.3 | 0.3 | 0 |
| Hashimoto's thyroiditis | 1 | 0.1 | 9 |
| Heart Failure | 1 | 1 | 0 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.2 | -0.2 | |
| hyperglycemia | 0.7 | 0.8 | -0.14 |
| Hyperlipidemia (High Blood Fats) | 0.1 | 0.1 | |
| hypertension (High Blood Pressure | 1.4 | 1.3 | 0.08 |
| Hypothyroidism | 0.1 | 0.3 | -2 |
| Hypoxia | 0.5 | 0.5 | |
| IgA nephropathy (IgAN) | 1.3 | 0.5 | 1.6 |
| Inflammatory Bowel Disease | 1.5 | 2.4 | -0.6 |
| Insomnia | 0.4 | 1.5 | -2.75 |
| Intracranial aneurysms | 0.7 | 0.7 | |
| Irritable Bowel Syndrome | 1.5 | 1.9 | -0.27 |
| ischemic stroke | 1.1 | 0.5 | 1.2 |
| Liver Cirrhosis | 2.1 | 2.1 | 0 |
| Long COVID | 1.7 | 1.5 | 0.13 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.5 | -0.5 | |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | 0 |
| ME/CFS with IBS | 0.9 | 0.9 | |
| ME/CFS without IBS | 0.9 | 0.2 | 3.5 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.7 | -1.33 |
| Metabolic Syndrome | 2 | 1.9 | 0.05 |
| Mood Disorders | 3.9 | 2.2 | 0.77 |
| multiple chemical sensitivity [MCS] | 0.5 | 0.5 | |
| Multiple Sclerosis | 2.1 | 1.8 | 0.17 |
| Multiple system atrophy (MSA) | 0.4 | 0.3 | 0.33 |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 0.3 | 1.1 | -2.67 |
| Neuropathy (all types) | 0.7 | 1 | -0.43 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.1 | 1.2 | -0.09 |
| NonCeliac Gluten Sensitivity | 0.5 | 0.5 | |
| Obesity | 2.7 | 2.9 | -0.07 |
| obsessive-compulsive disorder | 0.9 | 0.5 | 0.8 |
| Osteoarthritis | 0.3 | 0.7 | -1.33 |
| Osteoporosis | 1.1 | 0.5 | 1.2 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 2.7 | 1.7 | 0.59 |
| Polycystic ovary syndrome | 1.9 | 1.4 | 0.36 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.3 | 0 |
| Primary sclerosing cholangitis | 0.7 | 0.9 | -0.29 |
| Psoriasis | 0.7 | 1.4 | -1 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.1 | 0.5 | 3.2 |
| Rosacea | 0.3 | 0.5 | -0.67 |
| Schizophrenia | 1.5 | 1.4 | 0.07 |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 0.7 | 0.4 | 0.75 |
| Sleep Apnea | 0.3 | 1.1 | -2.67 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 1.1 | 1.5 | -0.36 |
| Systemic Lupus Erythematosus | 1 | 0.8 | 0.25 |
| Tic Disorder | 0.6 | 0.6 | |
| Tourette syndrome | 0.4 | 0.4 | |
| Type 1 Diabetes | 0.8 | 1.1 | -0.38 |
| Type 2 Diabetes | 2.6 | 1.9 | 0.37 |
| Ulcerative colitis | 0.7 | 1.6 | -1.29 |
| Unhealthy Ageing | 1.2 | 1.1 | 0.09 |
| Vitiligo | 1 | 0.5 | 1 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
